Literature DB >> 16315019

Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement.

Raphael Schiffmann1, Amy Rapkiewicz, Mones Abu-Asab, Markus Ries, Hasan Askari, Maria Tsokos, Martha Quezado.   

Abstract

We describe the postmortem findings of a 47-year-old man with Fabry disease, an X-linked glycolipid storage disorder, who was on enzyme replacement therapy with recombinant alpha-galactosidase A for more than 2 years. The patient had widespread atherosclerotic coronary artery disease that culminated in a massive acute myocardial infarction. Atherosclerotic lesions were seen in the right and left coronary systems, aorta, and the basilar artery. Typical Fabry cardiomyopathy and glomerular nephropathy were found. With the exception of vascular endothelial cells, extensive glycolipid storage deposits were seen in all vascular and nonvascular cells and organ systems. We conclude that, at least in this patient, repeated infusions with alpha-galactosidase A over a prolonged period did not appreciably clear storage material in cells other than vascular endothelial cells. These findings also illustrate accelerated atherosclerosis in susceptible patients with Fabry disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16315019      PMCID: PMC2288734          DOI: 10.1007/s00428-005-0089-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  21 in total

1.  Fabry disease: an unusual cause of severe coronary disease in a young man.

Authors:  E A Fisher; R J Desnick; R E Gordon; C M Eng; R Griepp; M E Goldman
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

2.  Fabry disease. A case report.

Authors:  Jozica Kotnik; Franc Kotnik; Robert J Desnick
Journal:  Acta Dermatovenerol Alp Pannonica Adriat       Date:  2005-03

3.  Case 2-1984: Fabry's disease.

Authors: 
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

4.  Neuropathological and biochemical studies in Fabry's disease.

Authors:  T Tabira; I Goto; Y Kuroiwa; M Kikuchi
Journal:  Acta Neuropathol       Date:  1974       Impact factor: 17.088

5.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

Authors:  R O Brady; A E Gal; R M Bradley; E Martensson; A L Warshaw; L Laster
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

6.  Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency.

Authors:  Peter F Bodary; Yuechun Shen; Fernando B Vargas; Xiaoming Bi; Kristen A Ostenso; Shufang Gu; James A Shayman; Daniel T Eitzman
Journal:  Circulation       Date:  2005-01-24       Impact factor: 29.690

7.  Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre.

Authors:  Thanh T Nguyen; Trevor Gin; Kathy Nicholls; Michael Low; Jason Galanos; Andrew Crawford
Journal:  Clin Exp Ophthalmol       Date:  2005-04       Impact factor: 4.207

8.  Effect of genetic modifiers on cerebral lesions in Fabry disease.

Authors:  Gheona Altarescu; David F Moore; Raphael Schiffmann
Journal:  Neurology       Date:  2005-06-28       Impact factor: 9.910

9.  Angiokeratoma corporis diffusum universale (Fabry's disease): a case with gross myocardial involvement.

Authors:  C Duncan; G M McLeod
Journal:  Australas Ann Med       Date:  1970-02

10.  Involvement of dorsal root ganglia in Fabry's disease.

Authors:  N Gadoth; U Sandbank
Journal:  J Med Genet       Date:  1983-08       Impact factor: 6.318

View more
  32 in total

1.  A Short Synthetic Peptide Mimetic of Apolipoprotein A1 Mediates Cholesterol and Globotriaosylceramide Efflux from Fabry Fibroblasts.

Authors:  Ulrike Schueler; Christine Kaneski; Alan Remaley; Stephen Demosky; Nancy Dwyer; Joan Blanchette-Mackie; John Hanover; Roscoe Brady
Journal:  JIMD Rep       Date:  2015-12-19

2.  Cellular and tissue localization of globotriaosylceramide in Fabry disease.

Authors:  Hasan Askari; Christine R Kaneski; Cristina Semino-Mora; Priya Desai; Agnes Ang; David E Kleiner; Lorah T Perlee; Martha Quezado; Linda E Spollen; Brandon A Wustman; Raphael Schiffmann
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

3.  Chronic meningitis and lacunar stroke in Fabry disease.

Authors:  W Schreiber; A Udvardi; W Kristoferitsch
Journal:  J Neurol       Date:  2007-10-25       Impact factor: 4.849

4.  Cellular and tissue distribution of intravenously administered agalsidase alfa.

Authors:  Gary J Murray; Miriam R Anver; Maureen A Kennedy; Jane M Quirk; Raphael Schiffmann
Journal:  Mol Genet Metab       Date:  2006-12-22       Impact factor: 4.797

5.  Intravascular ultrasound assessment of coronary artery involvement in Fabry disease.

Authors:  T Kovarnik; G S Mintz; D Karetova; J Horak; J Bultas; R Skulec; H Skalicka; M Aschermann; M Elleder; A Linhart
Journal:  J Inherit Metab Dis       Date:  2008-11-08       Impact factor: 4.982

6.  Functional studies of new GLA gene mutations leading to conformational Fabry disease.

Authors:  C Filoni; A Caciotti; L Carraresi; C Cavicchi; R Parini; D Antuzzi; A Zampetti; S Feriozzi; P Poisetti; S C Garman; R Guerrini; E Zammarchi; M A Donati; A Morrone
Journal:  Biochim Biophys Acta       Date:  2009-11-24

7.  Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease.

Authors:  Gregory M Pastores
Journal:  Biologics       Date:  2007-09

Review 8.  Unusual renal presentation of Fabry disease in a female patient.

Authors:  Cataldo Abaterusso; Vincenzo De Biase; Alessandro Salviati; Antonia Fabris; Deborah Millardi; Paola Tomei; Patrizia Bernich; Antonio Lupo; Giovanni Gambaro
Journal:  Nat Rev Nephrol       Date:  2009-04-28       Impact factor: 28.314

9.  Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

Authors:  Fernando C Fervenza; Roser Torra; David G Warnock
Journal:  Biologics       Date:  2008-12

10.  Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients.

Authors:  Jana Keslová-Veselíková; Helena Hůlková; Robert Dobrovolný; Befekadu Asfaw; Helena Poupetová; Linda Berná; Jakub Sikora; Lubor Golán; Jana Ledvinová; Milan Elleder
Journal:  Virchows Arch       Date:  2008-03-20       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.